

## MELAN ACCRUAL REPORT - Open and Recently Closed Studies

| SWOG/<br>Support | STUDY  | O<br>R P<br>E E<br>G N | ARM | ACCR.<br>GOAL             | TOTAL<br>REGS. | REGS.               | REGS.              | REGS.              | REGS.              | REGS.             | DATE<br>OF<br>FIRST<br>REG. | # of<br>ACT.<br>INSTs | # of<br>CURR<br>IRBs |     |
|------------------|--|------------------------|-----|---------------------------|----------------|---------------------|--------------------|--------------------|--------------------|-------------------|-----------------------------|-----------------------|----------------------|-----|
|                  |  |                        |     |                           |                | LAST<br>12<br>Month | LAST<br>6<br>Month | LAST<br>3<br>Month | LAST<br>30<br>DAYS | LAST<br>7<br>DAYS |                             |                       |                      |     |
| SWOG             | S1320-Adv, BRAF mut, Inter v Contin              | 1                      | Y 1 | Lead-in Continuous Dosing | 280            | 152                 | 57                 | 29                 | 18                 | 5                 | 5                           | 09/19/2014            | 242                  | 100 |
|                  |  |                        |     |                           |                | 152                 | 57                 | 29                 | 18                 | 5                 | 5                           |                       |                      |     |
|                  |  | 2                      | Y 2 | Continuous Dosing         | 280            | 59                  | 18                 | 10                 | 6                  | 2                 | 2                           | 09/19/2014            |                      |     |
|                  |  |                        |     | 3 Intermittent Dosing     |                | 61                  | 21                 | 13                 | 6                  | 0                 | 0                           |                       |                      |     |
|                  |  |                        |     |                           |                | 120                 | 39                 | 23                 | 12                 | 2                 | 2                           |                       |                      |     |
|                  | S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475   | 1                      | Y 1 | Tissue for PD-L1 testing  | 1378           | 1150                | 980                | 545                | 279                | 92                | 20                          | 11/10/2015            | 416                  | 174 |
|                  |  |                        |     |                           |                | 1150                | 980                | 545                | 279                | 92                | 20                          |                       |                      |     |
|                  |  | 2                      | Y 2 | FDA approved regimen      | 1378           | 525                 | 460                | 268                | 130                | 38                | 15                          | 11/10/2015            |                      |     |
|                  |  |                        |     | 3 MK-3475 (Pembrolizumab) |                | 518                 | 454                | 254                | 132                | 39                | 8                           |                       |                      |     |
|                  |  |                        |     |                           |                | 1043                | 914                | 522                | 262                | 77                | 23                          |                       |                      |     |
|                  | S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | 1                      | Y 1 | MK-3475 (pembrolizumab)   | 77             | 1                   | 1                  | 1                  | 0                  | 0                 | 0                           | 02/06/2017            | 49                   | 20  |
|                  |  |                        |     |                           |                | 1                   | 1                  | 1                  | 0                  | 0                 | 0                           |                       |                      |     |
| Yes              | EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 1                      | E   | Total Registrations       |                | 16                  | 12                 | 5                  | 3                  | 1                 | 0                           | 11/03/2015            | 340                  | 137 |
|                  |  |                        |     |                           |                | 16                  | 12                 | 5                  | 3                  | 1                 | 0                           |                       |                      |     |
|                  |  | 2                      | E   | Total Registrations       |                | 3                   | 3                  | 1                  | 0                  | 0                 | 0                           | 11/03/2015            |                      |     |
|                  |  |                        |     |                           |                | 3                   | 3                  | 1                  | 0                  | 0                 | 0                           |                       |                      |     |
|                  | EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim    | 1                      | E   | Total Registrations       |                | 30                  | 28                 | 17                 | 12                 | 8                 | 1                           | 03/25/2016            | 263                  | 102 |
|                  |  |                        |     |                           |                | 30                  | 28                 | 17                 | 12                 | 8                 | 1                           |                       |                      |     |
| No               | E3612-MELAN, Adv Ipilimumab±Bevacizumab          | 1                      | E   | Total Registrations       |                | 5                   | 1                  | 0                  | 0                  | 0                 | 0                           | 02/16/2015            | 146                  | 56  |
|                  |  |                        |     |                           |                | 5                   | 1                  | 0                  | 0                  | 0                 | 0                           |                       |                      |     |